Trial · NCT01353313
Outcomes40
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 40
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Survival Without Moderate/Severe Physiologic Bronchopulmonary Dysplasia (BPD) | From day of randomization to 36 weeks post menstrual age | The analysis population includes all randomized infants with available data at hospital discharge. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Survival Without Moderate/Severe Neurodevelopmental Impairment (NDI) | From day of randomization to 22-26 months corrected age | The analysis population includes all randomized infants with available data at the two-year followup. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Successful Extubation | From day of randomization to day 14 post randomization | The analysis population includes all randomized infants with available data at hospital discharge. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Total Deaths Before Discharge | From day of randomization to Neonatal Research Network NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth | The analysis population includes all randomized infants with available data at hospital discharge. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Bronchopulmonary Dysplasia (BPD) Grade at 36 Weeks Postmenstrual Age | At 36 weeks postmenstrual age | The analysis population includes all randomized infants with available data at hospital discharge. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Days of Mechanical Ventilation to 36 Weeks Postmenstrual Age (PMA) | From birth to 36 weeks postmenstrual age | The analysis population includes all randomized infants with available data at hospital discharge. | Days | MEDIAN |
| SECONDARY | Duration of Oxygen Supplementation up to Status | From birth to Neonatal Research Network NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth | The analysis population includes all randomized infants with available data who survived up to hospital discharge. | Days | MEDIAN |
| SECONDARY | Length of Hospital Stay in Days Among Survivors to Discharge | From birth up to one year | The analysis population includes all randomized infants with available data at hospital discharge. | Days | MEDIAN |
| SECONDARY | Number of Participants With Dexamethasone Given Before 36 Weeks Postmenstrual Age (PMA) | From birth to 36 weeks postmenstrual age | The analysis population includes all randomized infants with available data at hospital discharge. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Normal/Mild, Moderate or Severe/Profound NDI | At 22-26 months corrected age | The analysis population includes all randomized infants with available data who survived up to the two-year followup. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Gross Motor Function Greater Than or Equal to Level 2 | At 22-26 months corrected age | The analysis population includes all randomized infants with available data who survived up to the two-year followup. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Moderate-severe Cerebral Palsy | At 22-26 months corrected age | The analysis population includes all randomized infants with available data who survived up to the two-year followup. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Severe Hearing Impairment (by Report) | At 22-26 months corrected age | The analysis population includes all randomized infants with available data who survived up to the two-year followup. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With no/Some Functional Vision | At 22-26 months corrected age | The analysis population includes all randomized infants with available data who survived up to the two-year followup. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Weight Growth Measure Following Extremely Preterm Birth | At 36 weeks post-menstrual age | The analysis population includes all randomized infants with available data between 35 and 37 weeks at discharge. | Z-score | MEAN |
| SECONDARY | Follow-up Weight Growth Measure Following Extremely Preterm Birth | At 22-26 months corrected age | The analysis population includes all randomized infants with available data between 18 and 30 months at follow-up. | Z-score | MEAN |
| SECONDARY | Length Growth Measure Following Extremely Preterm Birth | At 36 weeks post-menstrual age | The analysis population includes all randomized infants with available data between 35 and 37 weeks at discharge. | Z-score | MEAN |
| SECONDARY | Follow-up Length Growth Measure Following Extremely Preterm Birth | At 22-26 months corrected age | The analysis population includes all randomized infants with available data between 18 and 30 months at follow-up. | Z-score | MEAN |
| SECONDARY | Head Circumference Growth Measure Following Extremely Preterm Birth | At 36 weeks post-menstrual age | The analysis population includes all randomized infants with available data between 35 and 37 weeks at discharge. | Z-score | MEAN |
| SECONDARY | Follow-up Head Circumference Growth Measure Following Extremely Preterm Birth | At 22-26 months corrected age | The analysis population includes all randomized infants with available data between 18 and 30 months at follow-up. | Z-score | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01353313/outcomes